Should Apixaban (Eliquis) Be Held in Acute Rhabdomyolysis?
Apixaban should generally be continued in patients with acute rhabdomyolysis unless there is active bleeding, severe acute kidney injury requiring dialysis, or hemodynamic instability that necessitates urgent procedures. The decision hinges on the severity of kidney injury and bleeding risk rather than the rhabdomyolysis diagnosis itself.
Clinical Decision Framework
Assess Renal Function Immediately
The critical factor is not the rhabdomyolysis per se, but the degree of acute kidney injury (AKI) it causes. Measure creatinine clearance using the Cockcroft-Gault formula 1, 2.
Continue apixaban at current dose if:
- CrCl remains >30 mL/min AND
- No active bleeding AND
- Patient hemodynamically stable
Reduce apixaban dose to 2.5 mg BID if:
Hold apixaban temporarily if:
- CrCl <15 mL/min or requiring acute dialysis 4, 3
- Active bleeding or high bleeding risk procedures needed 5, 2
- Hemodynamic instability requiring urgent intervention
Monitor for Bleeding Risk
Rhabdomyolysis itself does not directly contraindicate anticoagulation 6. However, the complications—particularly severe AKI—increase bleeding risk substantially 7, 8.
Key bleeding risk factors to assess:
- Concomitant antiplatelet agents (significantly increases bleeding risk) 7
- BMI (lower BMI associated with higher bleeding risk in renal impairment) 8
- Need for urgent procedures or invasive lines
- Coagulopathy from liver involvement or DIC
Research shows that apixaban use in AKI results in 7.8% major bleeding rate compared to 3.4% without AKI 7. This is clinically significant but not prohibitive if the thromboembolic risk justifies continued anticoagulation.
Thromboembolic Risk Assessment
High-risk patients who should continue anticoagulation despite AKI:
- CHADS₂ score ≥3 9
- Mechanical heart valve 9
- Recent stroke/TIA within 3 months 9
- Active VTE requiring treatment 10
Lower-risk patients where temporary hold is reasonable:
- CHADS₂ score 0-1 with no recent thromboembolic events
- Completed VTE treatment course (>6 months) 2
Practical Management Algorithm
Step 1: Check CrCl and assess for active bleeding
- CrCl >30 mL/min + no bleeding → Continue current dose
- CrCl 15-30 mL/min → Reduce to 2.5 mg BID 3, 2
- CrCl <15 mL/min → Hold temporarily, reassess daily
Step 2: If holding apixaban:
- No bridging anticoagulation needed for most patients 11, 12
- Consider bridging only if CHADS₂ ≥3 or mechanical valve 9
- Restart when CrCl improves to >15 mL/min and hemostasis secured
Step 3: Timing of restart after hold:
- Wait 24-48 hours after hemostasis if low bleeding risk 12, 9
- Wait 48-72 hours if high bleeding risk procedure performed 9, 11
- Apixaban has rapid onset (3-4 hours to peak effect), so no loading dose needed 2
Critical Caveats
Apixaban accumulation in severe AKI: While apixaban is only 25% renally cleared (better than dabigatran at 80%), it still accumulates in severe renal dysfunction 4, 13. Patients with CrCl <15 mL/min show increased drug exposure and bleeding risk 8.
Avoid concomitant P-gp/CYP3A4 inhibitors: If patient is on ketoconazole, itraconazole, or ritonavir, reduce apixaban dose by 50% or avoid if already on 2.5 mg BID 2.
Dialysis considerations: Hemodialysis does NOT effectively remove apixaban 2. If patient requires emergent dialysis for rhabdomyolysis, the drug will persist. Recent data suggests 2.5 mg BID may be reasonable in dialysis patients, though evidence is limited 4, 8.
No routine monitoring helpful: PT, INR, aPTT, and anti-Xa levels are not reliable for apixaban dosing decisions in this setting 11, 2.
When Reversal is Needed
If life-threatening bleeding occurs with apixaban on board:
- Andexanet alfa is the specific reversal agent for factor Xa inhibitors 5
- Prothrombin complex concentrate (PCC) if andexanet unavailable 2
- Activated charcoal if within 2-4 hours of last dose 2
- Hemodialysis is NOT effective for apixaban removal 2
The key principle: rhabdomyolysis alone is not an indication to stop anticoagulation—the decision depends entirely on the severity of resulting AKI, bleeding risk, and thromboembolic risk balance 7, 13, 6.